RIL
NVCT icon

Rothschild Investment LLC’s Nuvectis Pharma NVCT Stock Holding History

Rothschild Investment LLC’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423 Buy
23
+22
+2,200% +$246 ﹤0.01% 3301
2026
Q1 		$8 Buy
+1
New +$9 ﹤0.01% 3583

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Rothschild Investment LLC's NVCT Position: Q2 2026 in Review

Rothschild Investment LLC increased its Nuvectis Pharma (NVCT) stake by 2,200% in Q2 2026, buying an estimated $246 and bringing the position to 23 shares worth $423. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

Rothschild Investment LLC first reported a position in NVCT in Q1 2026 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Rothschild Investment LLC held 23 shares of Nuvectis Pharma worth $423 as of Q2 2026.
  • Rothschild Investment LLC bought 22 Nuvectis Pharma shares in Q2 2026, an estimated $246.
  • Nuvectis Pharma made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3301 holding.
  • Rothschild Investment LLC first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.